摘要
目的探讨利拉萘酯软膏治疗体股癣的疗效和安全性。方法采用多中心、随机双盲、有效对照、平行分组法对144例体股癣患者进行了4周的临床研究。结果138例患者完成临床观察并纳入统计分析,其中试验组71例,对照组67例,试验组治愈率为46.48%,对照组为40.30%,两组有效率分别为83.10%和83.58%,真菌清除率分别为95.83%和95.65%;不良反应发生率分别为0.70%和0。两组之间的临床治愈率、有效率和真菌清除率及不良反应率差异均无显著性。结论2%利拉萘酯软膏治疗体股癣综合疗效和不良反应发生率与1%联苯苄唑软膏相似,具有较好的疗效和安全性。
Objective To study the efficacy and safety of Liranaftate cream in the topical treatment of tinea cruris and tinea corporis, Methods Clinical study was done on 144 cases of tinea cruris and tinea corporis for 4 weeks with a multiple-centre, randomized, double-bind ,parallel trial. Results 138 cases have been studied, 71 were in the test group ,67 were in controlled group respectively . The total cure rate was 4 6. 4 8 % in the test group , and 4 0, 3 0 % in controlled group. The total efficacy rate was 83, 10% in test group,and 83.58% in controlled group, The total mycological cure rate was 95, 83% in test group,and 95, 65% in controlled group, The side-effect rate was 0, 70% in the test group, and zero in controlled group. There were no signifficant differences in clinical efficacy, mycological efficacy and side-effect between this two groups, Conclusion 2% Topical Liranaftate cream had a good efficacy and safety profile in the treatment of tinea cruris and tinea corporis.
出处
《中国皮肤性病学杂志》
CAS
北大核心
2006年第7期411-413,共3页
The Chinese Journal of Dermatovenereology
关键词
利拉萘酯
联苯苄唑
体股癣
Liranaftate
Tinea Corporis
Tinea Cruris
